PARANEOPLASTIC AB EVAL W/REFL TITER/LB, BASIC

What is a paraneoplastic antibody panel?

Paraneoplastic antibody panels look for autoantibodies associated with paraneoplastic neurologic syndromes (PNS). These are rare immune-driven conditions where the body’s immune response to a tumor accidentally targets parts of the nervous system (brain, spinal cord, peripheral nerves, neuromuscular junction, or cerebellum).

This “Basic” evaluation is typically used as a screening tool in people with neurologic symptoms that are not explained by more common causes (stroke, infection, vitamin deficiency, structural lesions, etc.).

Why this test may be ordered

Clinicians may order this panel when symptoms suggest an autoimmune or paraneoplastic process, such as:

• Rapidly worsening coordination or gait problems (ataxia)

• Peripheral neuropathy (numbness, tingling, burning pain)

• Weakness, fatigue, or autonomic dysfunction

• Confusion, memory loss, mood/personality changes

• Seizures or encephalitis-like symptoms

• Vision changes or abnormal eye movements

Because PNS can sometimes appear before a cancer is diagnosed, detecting a paraneoplastic antibody can prompt earlier cancer screening and treatment.

What “with reflex titer/line blot” means

This panel often follows a two-step approach:

1. Initial screening for a set of paraneoplastic antibodies

2. If positive or suspicious, the lab may reflex to:

   • Titer testing, which estimates antibody concentration/strength

   • Line blot (LB) confirmation, which improves specificity and reduces false positives

Reflex testing helps clarify whether a positive signal is clinically meaningful or more likely to be nonspecific.

How results are interpreted

A positive result does not automatically mean cancer is present, and a negative result does not completely rule out a paraneoplastic syndrome.

Interpretation depends on:

• Which antibody is present

• The strength/titer of the antibody

• The patient’s symptoms and exam findings

• MRI, EMG/NCS, EEG, spinal fluid results (CSF), and other autoimmune markers

• Whether symptoms are progressing quickly

Some antibodies are considered more strongly associated with cancer or neurologic syndromes than others, and some results can be low-level positives that require cautious interpretation.

What conditions can be associated with abnormal results

Paraneoplastic antibodies may be associated with:

• Paraneoplastic encephalitis or limbic encephalitis

• Cerebellar degeneration (ataxia)

• Sensory neuronopathy / neuropathy

• Stiff-person spectrum disorders

• Myelopathy (spinal cord dysfunction)

• Neuromuscular junction disorders (in some contexts)

They can also appear in non-cancer autoimmune neurologic disease, especially when symptoms fit but no tumor is found.

What to do if results are abnormal

If this panel is positive, common next steps include:

• Referral to neurology (often neuroimmunology)

• Targeted evaluation for underlying malignancy based on antibody pattern, age, sex, and risk factors

• Imaging such as CT chest/abdomen/pelvis, PET-CT, mammography, pelvic ultrasound, or testicular ultrasound (as appropriate)

• Additional autoimmune testing (CSF studies, MRI brain/spine, EMG/NCS)

• Treatment planning if autoimmune inflammation is suspected (often immunotherapy plus tumor treatment if found)

Early diagnosis matters because paraneoplastic neurologic syndromes may respond best when treated quickly.